Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
January 13, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Program Updates and Milestones for 2020

Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site Activation and Patient...
January 09, 2020 17:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Management Transition

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
January 06, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
December 17, 2019 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that...
November 13, 2019 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that...
November 12, 2019 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced...
November 11, 2019 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced...
November 04, 2019 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

Registrational Phase 2 Study of Repotrectinib Ongoing Phase 1/2 Clinical Studies of RET/SRC Inhibitor TPX-0046 and Repotrectinib in Pediatric Patients On Track to Initiate in 2019 Mohammad Hirmand,...
October 21, 2019 06:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Host Third Quarter 2019 Conference Call

SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report third...